Navigation Links
Perle BioScience Selects BlazeFund As Its Crowd Funding Platform

BOSTON, Sept. 4, 2013 /PRNewswire/ -- BlazeFund, a new equity crowd funding company in Boston, Massachusetts, has listed the first biotech company on their platform. Atlanta-based Perle BioScience is a life sciences company whose mission is to address patient needs that have been considered "impossible" to tackle.


Perle BioScience's founder, Dr. Claresa Levetan, is internationally recognized as a leader of diabetes research. She previously co-founded CureDM and was a lead inventor of a therapeutic drug for the reversal of diabetes. CureDM's IP portfolio was licensed to Sanofi in 2010 for upfront and commercial milestone payments of a potential value totaling $335M.

Dr. Levetan is raising capital for Perle BioScience to "pave the way for a revolutionary therapeutic treatment which will create a transformational shift in the treatment of diabetes," states Dr. Levetan. According to the American Diabetes Association, there are currently 26 million diabetes patients in the US.

Dr. Levetan indicates, "Nearly 1 out of 10 healthcare dollars or 4 out of 10 Medicare dollars are spent on patients with diabetes. As health care costs are spiraling and the diabetes population is growing, Perle BioScience is looking to address the underlying mechanisms that cause diabetes. Our treatment will be a huge benefit to society as a whole – not just for diabetic patients - but also in terms of managing healthcare costs."

Perle BioScience elected to utilize equity crowd funding to obtain the company's growth capital. Dr. Levetan mentions, "Perle is making a paradigm shift in the treatment of diabetes, and we specifically chose equity crowd funding, which is a perfect fit, since it is creating a paradigm shift as it relates to accessing capital. The ability to expose our company's technology to so many types of investors, from small to large, is invaluable. More importantly, we specifically selected BlazeFund based on their healthcare/ life science focus and the experience of their leadership team."

Aaron Sanders, CEO of BlazeFund, adds, "BlazeFund provides the entire investment community with exposure and access to innovative ventures. We are very proud and enthusiastic to be working with an industry leader that has the caliber of Perle BioScience."

For more information about BlazeFund please contact:
Aaron Sanders, CEO & Founder

SOURCE BlazeFund
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. 150,000 Medical Professionals Stay Paperless with Practice Fusion
2. Wacoms New DTU-1031 Provides Paperless Electronic Signature Solution for Businesses
3. Whats New with Flu this Season: Industry Recommendations, New Vaccines and 100% Paperless Flu Program Solution
4. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
5. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
6. PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
7. Genocea Biosciences Selected To Present Late-Breaking Oral Presentation At ICAAC 2013
8. Regado Biosciences, Inc. Announces Closing of Initial Public Offering
9. Sangamo BioSciences to Acquire Ceregene
10. PuraMed BioScience Sponsors Miles for Migraine Race with LipiGesic M
11. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015   Nuance Communications, Inc. ... National Decision Support Company (NDSC) today jointly announced ... collaboration capabilities that utilize the American College of Radiology,s ... provider organizations to comply with current and emerging ... --> By combining clinical decision support, ...
(Date:11/30/2015)... , Nov. 30, 2015  Novartis will demonstrate the ... 57 th American Society of Hematology (ASH) Annual ... myelomas as well as supportive care, including key findings ... personalized cell therapies. The ASH Annual Meeting will be ... . Novartis Oncology . "We will be ...
(Date:11/30/2015)... Israel , Nov. 30, 2015  OticPharma, Ltd., ... and developing innovative therapies for ear, nose, and throat ... A. Katkin as chairman of the company,s board ... executive officer for OticPharma, Ltd.  "Keith brings a wealth ... will be able to share this experience and provide ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Brenntag Specialties, Inc. (BSI) ... for the Nutraceutical Specialties products into oral solid dosage in the over the ... “We are pleased to announce our expanded distribution agreement with ASI.” said Steve ...
(Date:11/30/2015)... ... November 30, 2015 , ... An inventor from Charlottesville, Va., is ... "My last baby had high blood pressure due to loud noises," she said, "so ... babies from noise pollution as well as radio waves and microwaves." , The baby ...
(Date:11/30/2015)... ... November 30, 2015 , ... Since its ... specializing in independent living, assisted living and all other retirement options. Support for ... awareness and research remains a top priority. , So it’s no surprise ...
(Date:11/30/2015)... New York, New York (PRWEB) , ... November 30, 2015 , ... ... at the Greater New York Dental Meeting. Their Ecosystem empowers dentists to make complex ... Dentists who visit the booth will receive a free fee survey with 10 procedures ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... of DataTrade Solutions Inc., a Healthcare IT consulting, development and support company. The ... and technical experience available within DataTrade to extend the services currently provided by ...
Breaking Medicine News(10 mins):